Childhood acute lymphoblastic leukaemia - Current status and future perspectives

Lancet Oncology

Volumn 2, Issue 10, 2001, Pages 597-607

  Pui, Ching Hon ^a,b   Campana, Dario ^a,b   Evans, William E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ENZYME; EPIRUBICIN; GLUCOCORTICOID; GUANINE ARABINOSIDE; GW 506 U 78; HYDROCORTISONE; IMATINIB; MERCAPTOPURINE; METHOTREXATE; ONCOPROTEIN; PREDNISOLONE; PREDNISONE; PRODRUG; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; CANCER RADIOTHERAPY; CANCER THERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DNA POLYMORPHISM; DRUG DOSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESISTANCE; DRUG TARGETING; FEMALE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOST SUSCEPTIBILITY; HUMAN; INFANT; INHERITANCE; LEUKEMIA; LEUKEMOGENESIS; MALE; MEASUREMENT; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECOGNITION; REVIEW; THROMBOSIS; TREATMENT OUTCOME;

EID: 0035473994     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00516-2     Document Type: Review

References (75)

1. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995
2. Children's Cancer Group trials in childhood acute lymphoblastic leukemia
3. Co-operative study of the childhood acute lymphoblastic leukemia (COALL): Long-term follow-up trials 82, 85, 89, and 92
4. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report
5. Long-term results of treatment studies for childhood acute lymphoblastic leukemia. Pediatric Oncology Group studies from 1986-1994
6. Long-term results of total therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Childrens Research Hospital
7. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995
8. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukemia, 1980-1997
9. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium protocol 91-01
10. Prenatal origin of acute lymphoblastic leukaemia in children
11. Molecular genetics, natural history and demise of childhood leukaemia
12. Molecular tracking of leukaemogenesis: Insights from a triplet pregnancy
13. Breakage and fusion of the TEL(ETV6) gene in immature B lymphocytes induced by apoptogenic signals
14. Detection of the TELAM1 fusion gene expression in febrile children with virus infections
15. Biological and therapeutic aspects of infant leukemia
16. Topoisomerase II inhibitor-related acute myeloid leukemia
17. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion
18. A lack of functional NAD(P)H: Quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators
19. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia
20. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms
21. International Childhood Acute Lymphoblastic Leukemia Workshop: Sausalito, CA 30 November - December 2000
22. Sex differences in prognosis for children with acute Lymphoblastic leukemia
23. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study
24. Outcome of treatment of childhood cancer in black as compared with white children. The St Jude Childrens Research Hospital experience, 1962 through 1992
25. Acute lymphoblastic leukemia
26. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
27. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: A distinct biological entity with a marked propensity to undergo apoptosis
28. Pharmacogenomics: Translating functional genomics into rational therapeutics
29. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
30. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
31. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukemia
32. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
33. High incidence of secondary brain tumours after radiotherapy and antimetabolites
34. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells. Relation to thiopurine metabolism
35. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study
36. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
37. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
38. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
39. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia
40. New definition of remission of childhood acute lymphoblastic leukemia
41. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
42. Identification of novel markers for mentoring minimal residual disease in acute lymphoblasts leukemia
43. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group trial NHL-BFM 90
44. The Société Française d'Oncologie Pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia
45. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma
46. Intensified therapy for infants with acute lymphoblastic leukemia. Results from the Dana-Farber Cancer Institute Consortium
47. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
48. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of Childrens Cancer Group
49. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: A report from the Taiwan Pediatric Oncology Group
50. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia
51. Double delayed intensification improves event-free survival for children with intermediate risk acute lymphoblastic leukemia: A report from the Childrens Cancer Group
52. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
53. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T-cell lymphblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study
54. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia
55. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate
56. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study
57. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90
58. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
59. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastics leukemia
60. Prevalence and growth characteristic of malignant stem cells in B-lineage acute lymphoblastic leukemia
61. Continuing (maintenance) therapy in lymphoblastic leukemia: Lessons from MRC UKALL X
62. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathiopurine and mercaptopurine intolerance
63. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12 000 randomised children
64. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia
65. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia
66. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to Prednisone
67. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: A Pediatric Oncology Group report
68. Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukemia using genotype and immunophenotype
69. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: A Pediatric Oncology Group Study
70. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group
71. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: Frequency of occurrence and risk factors for their development
72. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G02010A variant, and futher prothrombotic risk factors
73. Visual and verbal short-term memory deficits in childhood leukemia survivors after intrathecal chemotherapy
74. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
75. Interleukin-4 variant (Bay 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells